We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.

Urticaria updates from ACAAI 2025 include data on dupilumab for chronic urticaria, the relative effectiveness of 55 ...

Regeneron Pharmaceuticals, Inc. ( REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM EST ...

EoE diagnosis is on the rise, and not all treatments have been successful. A Utah physician researcher explores how diet and ...

A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (“CSU”) in adults ...

(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for ...

In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...